EUVIMEDEUVIMED entdecken
Crossref

Retrospective Study on the Effectiveness and Outpatient Safety of Intravenous Ferric Carboxymaltose in Antenatal Anemia

Smriti Kumari, Chanchal Chanchal, Poonam Kumari

International Journal of Pharmaceutical Quality Assurance · 09.07.2026 · 16 (10)

DOI: 10.25258/ijpqa.16.10.72 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Pharmaceutical Quality Assurance, online erschienen am 09.07.2026. Verfasst von Smriti Kumari und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Iron deficiency anemia (IDA) is highly prevalent in pregnancy and is associated with adverse maternal and perinatal outcomes. Oral iron therapy is often limited by poor tolerance and inadequate response, especially in late gestation, prompting the use of intravenous preparations such as ferric carboxymaltose (FCM).

Aim

To retrospectively evaluate the effectiveness and outpatient safety of intravenous ferric carboxymaltose in the management of antenatal iron deficiency anemia. Methodology: This retrospective observational case–control study included 90 pregnant women with IDA at Department of Obstetrics and Gynaecology in Jannayak Karpoori Thakur Medical College and Hospital (JNKTMCH) Madhepura, Bihar, India. Seventy-two women received intravenous FCM (case group), while 18 eligible women managed with oral iron served as controls. Hematological parameters, obstetric outcomes, and adverse events were compared between groups.

Results

Baseline characteristics were comparable. The FCM group showed a significantly higher mean hemoglobin at delivery (10.7 ± 0.9 vs 9.0 ± 0.8 g/dL; p < 0.001), greater hemoglobin rise (+2.1 ± 0.8 vs +0.4 ± 0.6 g/dL), and a higher proportion achieving Hb ≥10 g/dL (72.2% vs 27.8%). Adverse effects were minimal (2.8%), with no serious reactions or hospital admissions.

Conclusion

Intravenous ferric carboxymaltose is an effective and safe outpatient treatment for antenatal IDA, providing superior hematological improvement without adverse obstetric or neonatal outcomes.

Zitieren

APA

Kumari, S., Chanchal, C., & Kumari, P. (2026). Retrospective Study on the Effectiveness and Outpatient Safety of Intravenous Ferric Carboxymaltose in Antenatal Anemia. International Journal of Pharmaceutical Quality Assurance, 16(10). https://doi.org/10.25258/ijpqa.16.10.72

Vancouver

Kumari S, Chanchal C, Kumari P. Retrospective Study on the Effectiveness and Outpatient Safety of Intravenous Ferric Carboxymaltose in Antenatal Anemia. International Journal of Pharmaceutical Quality Assurance. 2026;16(10). doi:10.25258/ijpqa.16.10.72

BibTeX
@article{Kumari2026,
  author = {Kumari, Smriti and Chanchal, Chanchal and Kumari, Poonam},
  title = {Retrospective Study on the Effectiveness and Outpatient Safety of Intravenous Ferric Carboxymaltose in Antenatal Anemia},
  journal = {International Journal of Pharmaceutical Quality Assurance},
  year = {2026},
  volume = {16},
  number = {10},
  doi = {10.25258/ijpqa.16.10.72}
}
Kostenlos starten →